-
China's transformation from a generics producer into a global biotech innovator
- Why leading pharma companies are increasingly licensing Chinese-developed therapies
- Explore the competitive advantages driving China's rapid drug development growth
- What China's rise means for western pharma, investors and policymakers
- And more....
Global Pharma and Biotech Summit
Changing patient behaviour, new computing power, rising political scrutiny and new global centres of innovation are redrawing pharma sector operating models. The result is not simply disruption, but also opportunity for those companies, investors and policymakers that can move early, think across silos, and build models that help take advantage of shifts.
The Global Pharma and Biotech Summit, organised by the Financial Times, will convene the leaders defining that next phase. Over two days at our annual London event, they will examine topics including Europe’s competitiveness, the US’s post-Most Favored Nation pricing regime, the latest applications of AI, direct access to medications, China’s influence and the future of the NHS. Each of the event sessions will address ways the pharma and biotech sectors can turn scientific momentum into commercial success, build stronger systems, and deliver better outcomes for patients.
Lawrence Tallon, CEO, Medicines and Healthcare products Regulatory Agency
Why Attend?
Understand
the technology and innovation behind new treatments with the power to transform healthcare.
Connect
with industry leaders responsible for the big decisions in areas such as investment, innovation and market access.
Discover
new ideas to support business transformation and maximise return on investment.
New report just released - China’s biotech boom: New dynamics in global drug development
Get your complimentary copy. Preview the themes, challenges and strategic questions that will be debated by industry leaders at the summit.
Inside you will find insight into:
Early bird offer now on!
THE EARLY BIRD
PHARMA & BIOTECH PASS
Gain access to in-person sessions and networking drinks. Network and connect with your peers.
£2,099
plus VAT
Full price £2,499 from 1 September 2026
THE EARLY BIRD
SUPPLIER PASS
Gain access to in-person sessions and networking drinks. Network and connect with your peers
£3,099
plus VAT
Full price £3,499 from 1 September 2026
Key themes
Geopolitical and Economic Disruptions:
The escalating political and economic tension between the US and China raises concerns about strategic de-coupling, affecting global R&D, manufacturing, and market access.
The Rise of New Pharma Powers:
India is recognised as a rapidly growing biotech hub, maturing beyond generic drugs and China is transitioning from a licensing market to a global innovation force.
Regulation of Emerging Technologies:
Regulators face challenges assessing complex technologies with limited transparency. Defining "evidence" in the context of AI and RWE is also a concern.
Drug Pricing and Reimbursement Pressures:
Balancing drug affordability with the need to fund innovation is a central challenge.
Patient Empowerment and Digital Health:
Apps, sensors, and digital platforms are reshaping patient interactions with therapies.
Supporting Partners
"I learned so much. We heard from practising doctors, government payers... Putting that spectrum together has been incredibly educational for me and really helpful for our practice" - Seth Ettenberg, President and CEO, BlueRock Therapeutics
Speaking Opportunities
Ben Graham
ben.graham@ft.com
Sponsorship
Rachel Joy
rachel.joy@ft.com
Delegate Services
Joshua Goddard
joshua.goddard@ft.com